Dose finding—a challenge in statistics.
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
A good understanding and characterization of the dose response relationship of any new compound is an important and ubiquitous problem in many areas of scientific investigation. This is especially true in the context of pharmaceutical drug development, where it is mandatory to launch safe drugs which demonstrate a clinically relevant effect. Selecting a dose too high may result in unacceptable safety problems, while selecting a dose too low may lead to ineffective drugs. Dose finding studies thus play a key role in any drug development program and are often the gate‐keeper for large confirmatory studies. In this overview paper we focus on definitive and confirmatory dose finding studies in Phase II or III, reviewing relevant statistical design and analysis methods. In particular, we describe multiple comparison procedures, modeling approaches, and hybrid methods combining the advantages of both. An outlook to adaptive dose finding methods is also given. We use a real data example to illustrate the methods, together with a brief overview of relevant software. (© 2008 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Simultaneous Inference in General Parametric Models
Hothorn, T., Bretz, F., & Westfall, P. (2008) · Biometrical Journal · doi:10.1002/bimj.200810425 · Cited by 13,847 · cited 1×
“Alternatively, simultaneous confidence lower or upper bounds for Dunnett’s 1-sided method can be computed with the multcomp package implemented in R (Bretz et al., 2008; Hothorn et al., 2008).”
MethodSelf-citationMixed-Effects Models in Sand S-PLUS
Pinheiro, J. C., & Bates, D. M. (2000) · Statistics and Computing · doi:10.1007/978-1-4419-0318-1 · Cited by 11,187
Self-citationA Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,094
Nonlinear Regression Analysis and Its Applications
Bates, D. M., & Watts, D. G. (1988) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316757 · Cited by 3,979
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Seber, G. A. F., & Wild, C. J. (1989) · Wiley Series in Probability and Statistics · doi:10.1002/0471725315 · Cited by 1,962
Assessment and Propagation of Model Uncertainty
Draper, D. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02015.x · Cited by 1,599 · cited 1×
“Ignoring model uncertainty thus can lead to highly undesirable effects, see Chatfield (1995), Draper (1995), and Hjorth (1994).”
BackgroundOrder Restricted Statistical Inference.
Santner, T., Robertson, T., Wright, F. T., & Dykstra, R. L. (1990) · Journal of the American Statistical Association · doi:10.2307/2289813 · Cited by 1,586
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423 · cited 1×
“This method is based on the closure principle (Marcus et al., 1976) for controlling the overall type I error rate.”
MethodGroup Sequential Methods with Applications to Clinical Trials
Jennison, C., & Turnbull, B. W. (1999) · Chapman & Hall/CRC eBooks · doi:10.1201/9780367805326 · Cited by 1,336
Research works printed but not linked: 3
- Bornkamp B.(2006).Comparison of model‐based and model‐free approaches for the analysis of dose response studies. Diploma thesis University of Dortmund.
- 1991, FDC Reports from May 6, 1991, The Pink Sheet, 53, 14
- 10.1080/10543400701645140 · doi:10.1080/10543400701645140
Cited by
Workgroup, E. M., Marshall, S., Burghaus, R., Cosson, V, Cheung, S., Chenel, M., DellaPasqua, O., Frey, N., Hamrén, B., Harnisch, L., et al. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12049 · Cited by 373
Dose-response meta-analysis of differences in means
Crippa, A., & Orsini, N. (2016) · BMC Medical Research Methodology · doi:10.1186/s12874-016-0189-0 · Cited by 202
“The most common choice in dose findings [2] is the use of the Emax model which is expressed in terms of three”
BackgroundMethodAerobic Exercise and Weight Loss in Adults: A Systematic Review and Dose-Response Meta-Analysis
Jayedi, A., Soltani, S., Emadi, A., Zargar, M.-S., & Najafi, A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.52185 · Cited by 172
Adjedj, J., Tóth, G. G., Johnson, N. P., Pellicano, M., Ferrara, A., Floré, V., Gioia, G. D., Barbato, E., Müller, O., & Bruyne, B. D. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.04.028 · Cited by 125
“Dose-response analysis was performed in 2 ways (14).”
Jayedi, A., Zeraattalab-Motlagh, S., Jabbarzadeh, B., Hosseini, Y., Jibril, A. T., Shahinfar, H., Mirrafiei, A., Hosseini, F., & Shab-Bidar, S. (2022) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqac066 · Cited by 85
Practical considerations for optimal designs in clinical dose finding studies
Bretz, F., Dette, H., & Pinheiro, J. C. (2010) · Statistics in Medicine · doi:10.1002/sim.3802 · Cited by 83
“For a recent general discussion of issues and challenges arising in clinical dose finding studies we refer to [2].”
Self-citationModel selection versus model averaging in dose finding studies
Schorning, K., Bornkamp, B., Bretz, F., & Holger Dette, A. (2016) · Statistics in Medicine · doi:10.1002/sim.6991 · Cited by 62
“We refer to, for example, [2] for an overview of both approaches, and the White Paper of the Pharmaceutical Research and Manufacturers of America (PhRMA) working group on adaptive dose ranging studies [3] for a comparison of different ANOVA and regression-based approaches.”
MethodSelf-citationResponse-adaptive dose-finding under model uncertainty
Bornkamp, B., Bretz, F., Holger Dette, A., & Pinheiro, J. (2011) · The Annals of Applied Statistics · doi:10.1214/10-aoas445 · Cited by 51
“First, they usually address two distinct objectives, which lead to different requirements on the study design [Ruberg (1995), Bretz et al. (2008)]: (i) assessing evidence of a drug effect, and (ii) estimating relevant target doses.”
BackgroundSelf-citationFunctional Uniform Priors for Nonlinear Modeling
Bornkamp, B. (2012) · Biometrics · doi:10.1111/j.1541-0420.2012.01747.x · Cited by 37
Crossley, S. A., & Skalicky, S. (2017) · Language Teaching · doi:10.1017/s0261444817000362 · Cited by 43
Simulation Practices for Adaptive Trial Designs in Drug and Device Development
Mayer, C., Perevozskaya, I. T., Leonov, S. L., Dragalin, V., Pritchett, Y., Bedding, A. W., Hartford, A. H., Fardipour, P., & Cicconetti, G. (2019) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2018.1560359 · Cited by 29
“…of dose–response curve where the biggest changes in efficacy/safety response are observed, or to reduce uncertainty of predictive probabilities (e.g., the probability that a given dose has adequate efficacy) or increase accuracy of the estimated target dose (e.g., MED, ED90) (Bretz et al. 2008).”
BackgroundVerrier, D., Sivapregassam, S., & Solente, A.-C. (2014) · Clinical Trials · doi:10.1177/1740774514532723 · Cited by 29
“The set of candidate models may include the following, where x designates the dose variable Linear ([3–8]): f(x, u) = E0 + dx Emax ([3–8]): f(x, u) = E0 + Emaxx/(ED50 + x) Logistic ([3–8]): f(x, u) = E0 + Emax/(1 + exp((ED50 2 x)/d)) Exponential ([3–6,8]): f(x, u) = E0 + E1(exp(x/d) 2 1) Log-linear ([3,6–8]): f(x, u)…”
MethodInfluentialDalton, E. J., Churilov, L. P., Lannin, N. A., Corbett, D., Campbell, B. C. V., & Hayward, K. S. (2021) · Neurorehabilitation and neural repair · doi:10.1177/15459683211019362 · Cited by 26
Dalton, E. J., Churilov, L. P., Lannin, N. A., Corbett, D., & Hayward, K. S. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01148 · Cited by 28
“, quantifiable amount of an active ingredient known to influence a specific therapeutic target) that reflects the dose of a given drug that is effective, safe, and tolerable (30).”
BackgroundEarly phase clinical trials in oncology: Realising the potential of seamless designs
Jaki, T., Burdon, A., Chen, X., Mozgunov, P., Zheng, H., & Baird, R. D. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.05.005 · Cited by 26
A Bayesian dose-response meta-analysis model: A simulations study and application.
Hamza, T., Cipriani, A., Furukawa, T. A., Egger, M., Orsini, N., & Salanti, G. (2021) · doi:10.48350/151952 · Cited by 23
Jayedi, A., Soltani, S., Emadi, A., Najafi, A., & Zargar, M. S. (2024) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.08.031 · Cited by 21
Gould, A. L. (2018) · Biometrical Journal · doi:10.1002/bimj.201700211 · Cited by 19
Biometrical Journal and Reproducible Research
Hothorn, T., Held, L., & Friede, T. (2009) · Biometrical Journal · doi:10.1002/bimj.200900154 · Cited by 21
“…and data was given by six articles (Piepho, Richter, and Williams, 2008; Häducke, Pahlke, and Ziegler, 2008; Kuss, Blankenburg, and Härting, 2008; Bretz et al., 2008; Hothorn, Bretz, and Westfall, 2008; Li et al., 2008), corresponding to 11% of articles that at least potentially can be seen as…”
AdaptiveDc‐optimal designs for dose finding based on a continuous efficacy endpoint
Padmanabhan, S. K., & Dragalin, V. (2010) · Biometrical Journal · doi:10.1002/bimj.200900214 · Cited by 18
“The importance and the challenges in designing and analyzing dose– response trials can be found in the ICH E4 (1994) guidance document and in the recent review papers by Gaydos et al. (2006), Bretz et al. (2008), and Dragalin (2010).”
BackgroundSverdlov, O., Ryeznik, Y. V., & Wong, W. K. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106397 · Cited by 18
Viele, K., & Connor, J. T. (2015) · JAMA · doi:10.1001/jama.2015.16702 · Cited by 16
Assessing the similarity of dose response and target doses in two non‐overlapping subgroups
Bretz, F., Möllenhoff, K., Dette, H., Liu, W., & Trampisch, M. (2017) · Statistics in Medicine · doi:10.1002/sim.7546 · Cited by 16
“4, we used again (7) to simulate nl,i = 6(30) observations at each dose level dl,i, resulting in nl = 30(150), l = 1, 2.”
MethodInfluentialSelf-citationMotaharinezhad, F., Emadi, A., Hosnian, M., Kheirkhahan, A., Jayedi, A., & Ehsani, F. (2024) · BMC Women s Health · doi:10.1186/s12905-024-03297-4 · Cited by 22
“In addition, determining the optimal exercise intensity for applying the most effective interventions in PCOS is very important [15, 16].”
BackgroundDose Response Signal Detection under Model Uncertainty
Holger Dette, A., Titoff, S., Stanislav Volgushev, A., & Bretz, F. (2015) · Biometrics · doi:10.1111/biom.12357 · Cited by 14
“As indicated in the Introduction, the MCP-Mod approach from Bretz et al. (2005) combines multiple comparison procedures with modeling techniques but ignores the specific structure of the regression models. In this article, we investigate an alternative procedure which is based on the likelihood ratio concept and uses…”
BackgroundMethodInfluentialSelf-citationColucci, E., Clark, A., Lang, C. E., & Pomeroy, V. M. (2017) · Physiotherapy · doi:10.1016/j.physio.2016.10.393 · Cited by 17
The impact of dropouts on the analysis of dose‐finding studies with recurrent event data
Akacha, M., & Benda, N. (2010) · Statistics in Medicine · doi:10.1002/sim.3930 · Cited by 14
“In fact, one of the main reasons for the high discontinuation rate of phase three clinical trials was found to lie in a poor understanding of the dose-response relationship and consequently in an inadequate dose selection, [1].”
BackgroundOptimal Designs for Dose Finding Studies with an Active Control
Dette, H., Kiss, C., Benda, N., & Bretz, F. (2013) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/rssb.12030 · Cited by 13
“This model was proposed by Bretz et al. (2005) as an alternative to the EMAX model and we assume as prior information for the unknown parameters μ=22:5, θ0 =2:5, θ1 =35:5, θ2 =50 and θ3 =10, and the target dose is given by dÅ =52:5.”
BackgroundMethodInfluentialSelf-citationAdaptive dose‐finding: Proof of concept with type I error control
Miller, F. (2010) · Biometrical Journal · doi:10.1002/bimj.200900222 · Cited by 13
“When an important goal of the study is to determine the best fitting dose–response shape among several candidates as it is done in the MCP-Mod method (see Bretz et al., 2005; Pinheiro et al., 2006), it is more reasonable to stick to prespecified response shapes and thereby to the prespecified contrasts. However, the c…”
MethodWang, K., Chen, X., Yang, F., Porter, D. W., & Wu, N. (2014) · ACS Sustainable Chemistry & Engineering · doi:10.1021/sc500102h · Cited by 12
Novel Statistical Designs for Phase I/II and Phase II Clinical Trials With Dose-Finding Objectives
Sverdlov, O., & Wong, W. K. (2014) · Therapeutic Innovation & Regulatory Science · doi:10.1177/2168479014523765 · Cited by 10
“Dunnett’s method73 can be used to obtain 100 1 ð aÞ% simultaneous lower confidence bounds on mk m0 for k ¼ 1; . . . ;K, and the lowest dose with the confidence bound greater than D can be chosen as a conservative estimate of the MED.21 One can also apply stepwise procedures by testing either a predefined sequence of h…”
BackgroundInfluentialTesting Effect of a Drug Using Multiple Nested Models for the Dose–Response
Baayen, C., Hougaard, P., & Pipper, C. B. (2015) · Biometrics · doi:10.1111/biom.12276 · Cited by 9
“Dose-finding studies are typically analyzed using one of two statistical approaches; comparing each dose separately to placebo using a multiple comparison procedure, or model- based strategies where a parametric model is fitted based on all data (Bretz et al., 2008).”
MethodMultiple comparisons in complex clinical trial designs
Hung, H., & Wang, S. (2013) · Biometrical Journal · doi:10.1002/bimj.201200048 · Cited by 9
“This kind of approach is essentially based on the concepts of alpha allocation and alpha propagation used interchangeably, as well articulated in Bretz et al. (2009) and Burman et al.”
BackgroundMethodInfluentialSpline‐based procedures for dose‐finding studies with active control
Helms, H., Benda, N., Zinserling, J., Kneib, T., & Friede, T. (2014) · Statistics in Medicine · doi:10.1002/sim.6320 · Cited by 8
“For a more detailed discussion of their MCPMod approach, we refer to [6,7].”
Dose finding by concentration-response versus dose-response: a simulation-based comparison
Berges, A., & Chen, C. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1474-z · Cited by 7
“Indeed, an accurate estimation of the dose-response would allow more confidence for the confirmatory trial; in the opposite, a poor choice of dose may lead to costly delays and the need to repeat studies or even drug failure [3].”
BackgroundMethodLiu, W., Zhou, S., & Bretz, F. (2013) · Australian & New Zealand Journal of Statistics · doi:10.1111/anzs.12048 · Cited by 7
Self-citationOptimal designs for frequentist model averaging
Alhorn, K., Schorning, K., & Dette, H. (2019) · Biometrika · doi:10.1093/biomet/asz036 · Cited by 7
Liu, W., Ah-Kine, P., Bretz, F., & Hayter, A. J. (2012) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2012.06.007 · Cited by 7
Self-citationBayesian dose selection design for a binary outcome using restricted response adaptive randomization
Meinzer, C., Martin, R. H., & Suárez, J. I. (2017) · Trials · doi:10.1186/s13063-017-2004-6 · Cited by 6
“Several approaches have been suggested in the literature, including phase I/II trials that search over a range of doses to identify the dose which optimizes safety and efficacy [1], methods that rank and select from a set of candidate doses [2], and hybrid designs that incorporate both aspects [3].”
BackgroundHelms, H., Benda, N., & Friede, T. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.920343 · Cited by 6
“For a more detailed discussion we refer to Bretz et al. (2008) and Pinheiro et al. (2006b).”
BackgroundMethodGeneralized multiple contrast tests in dose‐response studies
Ma, S., & McDermott, M. P. (2019) · Statistics in Medicine · doi:10.1002/sim.8444 · Cited by 6
“1) − 1; (iv) an exponential model exp ( 2d log(6) ) − 1; and (v) a sigmoid Emax model d4∕(d4 + 0.”
Optimal Designs for Model Averaging in non-nested Models
Alhorn, K., Dette, H., & Schorning, K. (2021) · Sankhya A · doi:10.1007/s13171-020-00238-9 · Cited by 6
Efficient Study Design and Analysis of Longitudinal Dose–Response Data Using Fractional Polynomials
Hartley, B. F., Lunn, D., & Mander, A. (2024) · Pharmaceutical Statistics · doi:10.1002/pst.2425 · Cited by 5
“Bretz et al. [4] describe the use of study design, modelling approaches, multiple comparison adjustments and combinations of methods to understand the dose– response relationship and select the correct dose.”
InfluentialIkeda, S., Sone, K., Takai, Y., Miyano, T., Negishi, K., Tsubota, K., & Kurihara, T. (2025) · BMC Ophthalmology · doi:10.1186/s12886-025-04213-6 · Cited by 5
“Understanding dose dependency plays a pivotal role in developing new drugs, as highlighted by studies conducted by Bretz et al. and Viele et al., which emphasized the importance of characterizing dose-response relationships to ensure safety and efficacy [15, 16].”
An example of optimal phase II design for exposure response modelling
Maloney, A., Schaddelee, M. P., Freijer, J. I., Krauwinkel, W. J. J., van Gelderen, M., Jacqmin, P., & Simonsson, U. S. H. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9168-y · Cited by 5
“Within the statistics field, the pivotal role of dose response studies is well recognized [ 20 ], both at the design [21] and analysis [22‐24] stages.”
Designing dose-finding studies with an active control for exponential families
Dette, H., Kettelhake, K., & Bretz, F. (2015) · Biometrika · doi:10.1093/biomet/asv041 · Cited by 5
“In most of the statistical literature on dose-response studies, a placebo is included as a control group (Bretz et al., 2008), and numerous authors have worked on optimal designs in such applications because the use of efficient designs can substantially increase the accuracy of statistical…”
BackgroundSelf-citationRen, X., & Xia, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210953 · Cited by 5
Optimal adaptive allocation using deep reinforcement learning in a dose‐response study
Matsuura, K., Honda, J., Hanafi, I. E., Sozu, T., & Sakamaki, K. (2021) · Statistics in Medicine · doi:10.1002/sim.9247 · Cited by 6
“In general, it is known that using p -values without considering adaptive allocation may inflate the type I error rate, and a simulation-based method to control the type I error rate has been discussed previously.”
MethodModel‐based approaches for time‐dependent dose finding with repeated binary data
Benda, N. (2010) · Statistics in Medicine · doi:10.1002/sim.3845 · Cited by 5
“Reference is also made to [4] and [5].”
BackgroundImproving Dose-Finding: A Philosophic View
Burman, C., Miller, F., & Wong, K. (2010) · CRC Press eBooks · doi:10.1201/b10279-11 · Cited by 5
Two-Stage Experimental Design for Dose–Response Modeling in Toxicology Studies
Wang, K., Yang, F., Porter, D. W., & Wu, N. (2013) · ACS Sustainable Chemistry & Engineering · doi:10.1021/sc4000412 · Cited by 4
Confidence bounds for nonlinear dose–response relationships
Baayen, C., & Hougaard, P. (2015) · Statistics in Medicine · doi:10.1002/sim.6566 · Cited by 6
“However, it can be more informative to fit a dose–response model to the data and to obtain information on the expected response for doses that have not been evaluated in the study itself [1].”
BackgroundSequential Methods in Multi-Arm Clinical Trials
Dragalin, V. (2010) · Sequential Analysis · doi:10.1080/07474946.2010.487416 · Cited by 4
Cohen, J. A., & Rudick, R. A. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.009 · Cited by 4
Kriging-Based Design of Experiments for Multi-Source Exposure–Response Studies in Nanotoxicology
Pei, Y., Yang, F., Chen, X., Wu, N., & Wang, K. (2017) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.6b02981 · Cited by 4
“One of the most fundamental steps in assessing the risk of a NM (or any other substance) is to characterize the NM by its exposure-response profile [10, 11], which describes the dependence of the adverse bioactivity effects (the responses) upon the NM exposure conditions [12].”
BackgroundA dose finding method in joint modeling of efficacy and safety endpoints in phase II studies
Tao, A. (2010) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t3gt5n82 · Cited by 4
Tepavčević, S., Zec, M. M., Stojiljković, M., Bošković, M., Ćulafić, T., Stanković, A., Romić, S., Živković, M., & Korićanac, G. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae173 · Cited by 4
Vandemeulebroecke, M., Bretz, F., Pinheiro, J. C., & Bornkamp, B. (2010) · CRC Press eBooks · doi:10.1201/b10279-12 · Cited by 3
Self-citationMcLaughlin, M. J., Ratnasingam, D., & McGhee, E. (2019) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001334 · Cited by 3
“In these studies, selecting a dose of oral baclofen that resulted in exposures, which were too low, may have led to ineffective treatment, whereas doses that resulted in exposures, which were too high, may have resulted in unacceptable safety profiles.(7) In addition, difficulty characterizing the factors underlying v…”
BackgroundAdaptive Design Across Stages of Therapeutic Development
Coffey, C. S. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139032445.010 · Cited by 6
The growing need for alternative clinical trial designs for multiple sclerosis
Reingold, S. C., McFarland, H. F., & Petkau, A. J. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9781139023986.024 · Cited by 2
Kågedal, M., Karlsson, M. O., & Hooker, A. C. (2015) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-015-9410-8 · Cited by 2
Rekowski, J., Köllmann, C., Bornkamp, B., Ickstadt, K., & Scherag, A. (2017) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2017.1293078 · Cited by 2
“Then we use for the purpose of this paper the second estimator of theMED proposed by Bretz et al. (2005), namely: bd 1⁄4 argmin d2ðd0;dk bμðdÞ > bμðd0Þ þ Δ; LðdÞ > bμðd0Þ f g:”
BackgroundMethodInfluentialSimultaneous confidence sets for several effective doses
Tompsett, D., Biedermann, S., & Liu, W. (2018) · Biometrical Journal · doi:10.1002/bimj.201700161 · Cited by 2
“…probability of observing a response in a subject; see its application to medicine and biology statistics in Finney (1971), to quantitative risk and hazard assessment in Piegorsch et al. (2005) and Peng et al. (2015), and to drug dose response curves in Carter et al. (1986) and Bretz et al. (2008).”
PHASE BEHAVIOUR OF FIRST - ORDER SYSTEMS
YANKOV, K. B. (2018) · Applied Researches in Technics Technologies and Education · doi:10.15547/artte.2018.02.008 · Cited by 2
Change point detection for clustered expression data
Sieg, M., Sciesielski, L. K., Kirschner, K. M., & Kruppa, J. (2022) · BMC Genomics · doi:10.1186/s12864-022-08680-9 · Cited by 2
“In the dose-response setting, multiple contrast tests are widely used [3–5].”
MethodKeene, O. N. (2014) · Wiley eBooks · doi:10.1002/9781118445112.stat07103 · Cited by 2
Jayedi, A., Khan, T. A., Mirrafiei, A., Ganjeh, B. J., Hosseini, Y., Zeraattalab-Motlagh, S., Jibril, A. T., Shahinfar, H., & Shab‐Bidar, S. (2021) · medRxiv · doi:10.1101/2021.05.21.21257564 · Cited by 2
“useful tools for determining the efficacy of increasing dose and selecting optimal dose for intervention (12, 13).”
BackgroundMethodOptimal dose de-escalation trial designs for novel contraceptives in women
Gerlinger, C., Siedentop, H., Gerke, O., Schellschmidt, I., & Endrikat, J. (2011) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2011.08.005 · Cited by 1
“The traditional escalation rule (TER) of Carter (1973), Edler and Burkholder (2006) and Korn et al. (1994) also known as the ‘‘3 + 3 design’’ in cancer trials, was adapted for contraception in the following way.”
BackgroundConsonant closed likelihood ratio test procedures with application to dose–response study
Wang, B., & Cui, X. (2010) · Statistics in Medicine · doi:10.1002/sim.4023 · Cited by 1
“[23] gave a review of modeling approaches and hybrid approaches combining multiple comparisons and modeling techniques.”
BackgroundMethodSoulakova, J. N., Sampson, A. R., Jia, G., & Gleser, L. J. (2011) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2010.504905 · Cited by 1
“( 2008 ) provided a thorough overview of a number of statistical approaches commonly used in dose-response studies.”
Ryeznik, Y. V., Sverdlov, O., & Hooker, A. C. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0242-5 · Cited by 2
Generalized Fiducial Inference for Threshold Estimation in Dose–Response and Regression Settings
Hwang, S., Lai, R. C. S., & Lee, T. C. M. (2021) · Journal of Agricultural Biological and Environmental Statistics · doi:10.1007/s13253-021-00472-0 · Cited by 2
“Existing statistical methods for threshold estimation in dose–response experiments can be broadly grouped into two different categories (Bretz et al. 2008): multiple comparison methods (Williams 1972; Ruberg 1989; Hsu and Berger 1999; Tamhane and Logan 2002; Guo and Li 2014; Otava et al.”
BackgroundMethodInfluentialSequential design for binary dose–response experiments
Yu, X., Chen, J., & Brant, R. (2016) · Journal of Statistical Planning and Inference · doi:10.1016/j.jspi.2016.04.005 · Cited by 1
“We refer to Ting (2006) and Bretz et al. (2008) for additional general discussion on issues and challenges in dose–response experiments in the context of the drug development process.”
BackgroundOptimal designs for model averaging in non-nested modelsPreprint
Alhorn, K., Dette, H., & Schorning, K. (2019) · arXiv (Cornell University) · doi:10.17877/de290r-19964 · Cited by 1
On Nonparametric Bayesian Analysis under Shape Constraints with Applications in Biostatistics
Bornkamp, B. (2009) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-8121 · Cited by 1
Wang, K. (2011) · doi:10.33915/etd.483
“These models represent the most frequently encountered dose-response shapes [3] and are expected to provide an adequate candidate pool for the relationship being investigated.”
BackgroundSoulakova, J. N., & Sampson, A. R. (2012) · Pharmaceutical Statistics · doi:10.1002/pst.542
“Likewise, a number of important problems related to single drug efficacy studies, for example, identifying all effective doses [17], the minimum effective dose [17, 18], and the optimal dose [17], and the corresponding statistical methods have been also recently proposed.”
BackgroundA Two-Stage Adaptive Design in Phase 2 Clinical Trials for Acute Treatment of Migraine
Fan, X. F., Assaid, C., Ge, Y. J., & Ho, T. W. (2011) · Drug Information Journal · doi:10.1177/009286151104500311
Wang, K. (2014) · doi:10.33915/etd.6902
“One of the most fundamental steps in assessing the risk of a nanomaterial (or any substance) is to understand and properly characterize its exposure-response relationship [8, 9].”
BackgroundZebarjadi, S., Soltanian, A. R., Faradmal, J., & Asgari, G. (2016) · مجله پزشکی بالینی ابن سینا · doi:10.21859/hums-23035
A Mixed Effect Emax Model Applied for Determination of Malathion Optimal Dose
Ranjbar, A., Zebarjadi, S., Naeini, M. K., & Soltanian, A. R. (2017) · Avicenna Journal of Medical Biochemistry · doi:10.15171/ajmb.2017.08
Optimal designs for frequentist model averagingPreprint
Alhorn, K., Schorning, K., & Dette, H. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1807.05234
Pei, Y. (2018) · doi:10.33915/etd.7226
“Herein, the scope of identifiers covers physicochemical properties of NMs, experimental conditions and study scenarios [20, 21].”
BackgroundModel identification for dose response signal detection
Bretz, F., Holger Dette, A., Titoff, S., & Stanislav Volgushev, A. (2012) · Technische Universität Dortmund Eldorado (Technische Universität Dortmund) · doi:10.17877/de290r-4910
“As indicated in the Introduction, the MCP-Mod approach has been advocated by several authors in the literature.”
BackgroundMethodSelf-citation(2010) · Chapman & Hall/CRC eBooks · doi:10.1201/9781420010909-c5
Keene, O. N. (2014) · Wiley eBooks · doi:10.1002/9781118596005.ch57
Reynolds, P. S. (2023) · Wiley eBooks · doi:10.1002/9781119800002.ch22
Bajuaifer, S. S., Grey, M. J., Hancock, N., Chandler, E., & Pomeroy, V. M. (2023) · Physiotherapy · doi:10.1016/j.physio.2023.10.007
Dufault, S. M., Aldana, B. H., & Phillips, P. P. J. (2025) · Trials · doi:10.1186/s13063-025-09050-y
“First, we implemented a closed testing approach, using a step-wise procedure similar to that described in [11].”
InfluentialOptimal designs for quasi-likelihood estimation in active controlled dose-finding trials
He, L., Yue, R., & Liu, X. (2025) · Journal of the Korean Statistical Society · doi:10.1007/s42952-025-00353-z
“Much of the work on dose-response studies in the statistical literature includes a placebo control group (see, for example, Pinheiro et al. ( 2006 ); Bretz et al. ( 2008 ) and Bretz et al. ( 2018 ), among others).”
Nonlinear Mixed Effects Methods for Improved Estimation of Receptor Occupancy in PET Studies
Kågedal, M. (2014) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Additional file 1 of Change point detection for clustered expression data
Sieg, M., Sciesielski, L. K., Kirschner, K. M., & Kruppa, J. (2022) · Figshare · doi:10.6084/m9.figshare.20252852
Early phase clinical trials in oncology: Realising the potential of seamless designs
Jaki, T., Burdon, A., Chen, X., Mozgunov, P., Zheng, H., & Baird, R. D. (2023) · University of Regensburg Publication Server (University of Regensburg) · doi:10.5283/epub.75717
Influence diagnostics and outlier detection for dose–response meta-analysis
Yamaguchi, K., Noma, H., Fujisawa, T., & Furukawa, T. A. (2026) · Biostatistics & Epidemiology · doi:10.1080/24709360.2025.2604384
Utility-based optimization of phase II / phase III clinical development
Aouni, J. (2019) · theses.fr (ABES) · doi:10.70675/d4196702z1607z4d6fzacbcz051618e1a8ac
Optimal Designs for Active Controlled Dose-Response Models with Asymmetric Errors
He, L., Yue, R., & Zheng, W. (2026) · Journal of Statistical Theory and Practice · doi:10.1007/s42519-026-00599-8
Metadata
- Authors
- Bretz, F., Hsu, J., Pinheiro, J., & Liu, Y.
- Affiliations
- Novartis (Switzerland) (CH)
- The Ohio State University (US)
- Corresponding author
- Bretz, Frank
- Venue
- Biometrical Journal
- Publisher
- Wiley
- Published
- 2008-07-29
- Volume
- 50
- Issue
- 4
- Pages
- 480-504
- ISSN
- 0323-3847 (ISSN-L)
- 1521-4036
- OpenAlex
- W1994654755
- Cited by
- 101
- References
- 68
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 3 · 2021: 7 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 9 · 2014: 9 · 2013: 6 · 2012: 6
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biometrical Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Management Science and Operations Research › Optimal Experimental Design Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- dose-finding, dose-response relationship, drug development, multiple comparisons, dose-response modeling, statistical design, phase II and III clinical trials
- MeSH terms
- Algorithms, Clinical Trials as Topic, Dose-Response Relationship, Drug, Pharmaceutical Preparations, Humans, Software, Models, Statistical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.